Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Hims & Hers (HIMS) is down -14.6%, or -$3.25 to $19.00. Published first on TheFly – the ultimate source for real-time, ...

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...

With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ...

The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are ...

Naturally, Dr. Hartman notes that to get the most out of shampoos designed for either regrowth or thickness, especially in more severe cases, they should be used alongside hair products that address ...

Telehealth companies selling low-cost, compounded versions of popular weight-loss drugs, including Ozempic and Wegovy, are drawing increased interest from employers, Bloomberg reported Oct. 29.

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...